Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DSP-0390 |
Synonyms | |
Therapy Description |
DSP-0390 inhibits emopamil binding protein (EBP), potentially resulting in decreased tumor cell proliferation and antitumor activity (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS2077; NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DSP-0390 | DSP 0390|DSP0390 | DSP-0390 inhibits emopamil binding protein (EBP), potentially resulting in decreased tumor cell proliferation and antitumor activity (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS2077; NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05023551 | Phase I | DSP-0390 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 1 |
NCT06636162 | Phase I | DSP-0390 | Window of Opportunity Study of DSP-0390 in Gliomas | Not yet recruiting | USA | 0 |